Tailored radiation beams aim to boost liver cancer treatment
NCT ID NCT03896646
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests whether giving liver cancer patients a personalized dose of radiation (Yttrium-90) can improve tumor shrinkage compared to standard dosing. The study includes 42 adults with advanced liver cancer that cannot be removed by surgery. Researchers use special scans to tailor the radiation dose to each patient's tumor and liver function, aiming to maximize effectiveness while minimizing harm.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Yttrium-90 radioembolization with personalized dosimetry
What this could lead to
If successful, this could make radiation therapy more effective for liver cancer patients who cannot have surgery, potentially improving tumor shrinkage and survival.
What could go wrong
This is a small, early-phase trial with only 42 participants, so results may not apply to everyone. Personalized dosing may not improve outcomes and could still cause liver damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III HEPATOCELLULAR CARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States